InsiderSignal.AI

InsiderSignal.ai

CING - Cingulate Inc.

Insider Purchase by Werth Peter J. (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 weeks ago, Werth Peter J., serving as Dir at Cingulate Inc. (CING), purchased 19,455 shares at $5.04 per share, for a total transaction value of $98,053.00. Following this transaction, Werth Peter J. now holds 117,541 shares of CING.

This purchase represents a 20.00% increase in Werth Peter J.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, February 6, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, February 10, 2026, 4 days after the trade was made.

Cingulate Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Werth Peter J.

Dir

Peter J. Werth is a seasoned pharmaceutical industry executive and current Director of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing next-generation products using its Precision Timed Release™ (PTR™) drug delivery platform for conditions like ADHD and anxiety disorders.[[1]](https://www.gurufocus.com/insider/185889/peter-j.-werth)[[2]](https://www.biospace.com/werth-family-investment-associates-converts-remaining-3-3m-of-debt-and-accrued-interest-into-cingulate-equity-at-premium-to-market)[[4]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cing/cingulate/management) He has served in this role since at least 2023, also designated as a 10 percent owner, and has been involved through Werth Family Investment Associates, LLC, where he serves as manager, converting debt into equity and participating in recent private placements, including the purchase of 19,455 shares and 15,564 warrants on February 6, 2026.[[1]](https://www.gurufocus.com/insider/185889/peter-j.-werth)[[2]](https://www.biospace.com/werth-family-investment-associates-converts-remaining-3-3m-of-debt-and-accrued-interest-into-cingulate-equity-at-premium-to-market)[[3]](https://www.stocktitan.net/sec-filings/CING/form-4-cingulate-inc-insider-trading-activity-d658c4b47398.html) Werth founded Chemwerth, Inc. in 1982, where he serves as Chief Executive Officer and President, focusing on the chemical aspects of the generic drug business, including research & development, sales, and marketing.[[5]](https://medrhythms.com/people/peter-werth/) His career highlights include prior work in R&D at Upjohn Pharmaceuticals (now Pfizer) from 1965 to 1975 and as Vice President of Sales and Marketing for Ganes Chemicals, a subsidiary of Siegfried Chemicals, before launching Chemwerth.[[5]](https://medrhythms.com/people/peter-werth/) As of recent filings, Werth directly holds 92 shares of CING and indirectly controls significant additional holdings through his entity.[[3]](https://www.stocktitan.net/sec-filings/CING/form-4-cingulate-inc-insider-trading-activity-d658c4b47398.html)

View full insider profile →

Trade Price

$5.04

Quantity

19,455

Total Value

$98,053.00

Shares Owned

117,541

Trade Date

Friday, February 6, 2026

16 days ago

SEC Filing Date

Tuesday, February 10, 2026

Filed 4 days after trade

HEALTHCAREBIOTECHNOLOGY

About Cingulate Inc.

Company Overview

No company information available
View news mentioning CING

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3872651

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime